Eledon Pharmaceuticals, Inc. (ELDN) Operating income 2016–2023
Eledon Pharmaceuticals, Inc. (ELDN) annual operating income history from SEC filings — each fiscal year as reported.
-$43.0MFY2023 · since FY2016: -$5.1M → -$43.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$43.0M | +51.4% |
| FY2022 | -$88.4M | -139.9% |
| FY2021 | -$36.9M | -99.7% |
| FY2020 | -$18.5M | -15.0% |
| FY2019 | -$16.1M | -14.2% |
| FY2018 | -$14.1M | -7.2% |
| FY2017 | -$13.1M | -155.9% |
| FY2016 | -$5.1M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ELDN financial trends
ELDN RevenueELDN Net incomeELDN Net marginELDN Gross profitELDN Gross marginELDN Operating marginELDN Operating cash flowELDN Free cash flowELDN Capital expendituresELDN Return on equityELDN Stock buybacksELDN Dividends paidELDN Total assetsELDN Total liabilitiesELDN Shareholders’ equityELDN overview →